ClinConnect ClinConnect Logo
Search / Trial NCT03550989

Real-Life Passive Exposure Assessment of IQOS

Launched by PHILIP MORRIS PRODUCTS S.A. · May 25, 2018

Trial Information

Current as of May 13, 2025

Completed

Keywords

Environmental Aerosol Exposure Environmental Tobacco Smoke Indoor Air Quality

ClinConnect Summary

The purpose of the study is to show that Non-Smokers, exposed to environmental tobacco aerosol from IQOS in a restaurant setting, do not have higher urinary levels of Biomarkers of Exposure (BoExp) to selected Harmful and Potentially Harmful Constituents (HPHCs), representative of Environmental Tobacco Smoke (ETS), compared to the urinary levels of BoExp measured in Non-Smokers before IQOS environmental tobacco aerosol exposure.

Furthermore, the impact of passive exposure to IQOS environmental tobacco aerosol on IQOS Users and Cigarette Smokers, not using any tobacco or nicotine-containing...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participant is able to understand the information provided in the Subject Information Sheet (SIS) and Informed Consent Form (ICF) (confirmed by signing the ICF) and has signed the ICF.
  • Adults legally authorized to buy tobacco products in Japan (20 years of age).
  • Participant is Japanese as self-reported.
  • Willing to participate in the study, comply with study procedures and has access to the Internet.
  • Participant is an active IQOS User, Cigarette smoker or Non-Smoker as self-reported
  • Exclusion Criteria:
  • Participant with a medical history of severe cardiovascular or respiratory diseases (e.g., stroke, acute cardiovascular event, pulmonary thrombosis) in the last 12 months as self-reported.
  • Participant with currently active cancer or history of cancer within the last 5 years as self-reported.
  • Female participant who is pregnant or breast-feeding as self-reported.
  • Participant is a current or former employee of the tobacco industry or their first-degree relatives (parent and child).
  • Participant is an employee of Philip Morris International (PMI), an employee of the Contract Research Organization (CRO) engaged for this study, an employee of the CRO's vendors, an employee of the restaurant/event location, or their first-degree relatives (parent or child).
  • Exclusion criteria specific to participants who are Non-Smokers:
  • Participant lives in a household with users of tobacco or nicotine-containing products, or is exposed to the use of tobacco or nicotine-containing products at the workplace.

About Philip Morris Products S.A.

Philip Morris Products S.A. is a leading global tobacco and nicotine product manufacturer, dedicated to transforming its business by developing and promoting smoke-free alternatives. With a strong emphasis on research and innovation, the company invests significantly in scientific studies to understand the health impacts of its products and to explore alternatives that reduce harm associated with traditional smoking. As a responsible industry leader, Philip Morris Products S.A. actively engages in clinical trials to evaluate the safety and efficacy of its reduced-risk products, contributing to the evolving landscape of tobacco harm reduction and public health.

Locations

Shibuya Ku, Tokyo, Japan

Patients applied

0 patients applied

Trial Officials

Patrick Picavet, MD

Study Chair

Philip Morris Products S.A.

Takao Ohki, MD, PhD

Principal Investigator

Jikei University School of Medicine, Tokyo

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials